Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — Q1 FY2023 Earnings Presentation
32 slides from Balaxi Pharmaceuticals's earnings presentation, Aug 2, 2022
Slide 1: Outcome of the Board Meeting
To 2nc.August, 2022 Listing Department National Stock Exchange of Ind·a Limited Exchange Plaza, Plot No C/1, G Block, BKC Bandra (E), Mumbai-400051 Stock Code: BAlAXI Sub: Outcome of the Board Meeting Dear Sir/ Madam, With reference to the above subject, we wish to inform you that the Board of Direc
Slide 2: Unaudited Consolidated Financial Results Q1 FY23
ANNEXtJRE -1 Balaxi Pharmaceuticals Limited 2nd Floor, :VL-\PSTowers, Plot no. 409, Road no. 81, Jubilee Hils, Phase Ill, Hvderabad-500096, Telangana Cl:-J:L25l 91TGl 942PLC121598 Un-audited Consolidated Financial Results for the quarter ended 30th June, 2022 (Rs. in Lakhs) Quarter Ended Year Ended
Slide 3: Auditor's Review Report - Consolidated
Tel. : (91-40) 2332 6666, 2331 2554 P. MURALI & CO., 23393967, 23321470 CHARTERED ACCOUNTANTS FAX : (91-40) 2339 2474 6-3-655/2/3, SOMAJIGUDA, E-mail : pmurali.co@gmail.com HYDERABAD - 500 082. INDIA info@pmurali.com Website : www.pmurali.com Independent Auditor's Review Report on the Quarterly Unau
Slide 4: Auditor's Review Report - Consolidated (continued)
Tel. : (91-Ll0) 2332 6666, 2331 2554 P. MURALI & CO., 2339 3967, 2332 1470 CHARTERED ACCOUNTANTS FAX : (91-~0) 2339 2474 6-3-655/2/3, SOMAJIGUDA, E-mail : pmurali.co@grnail.com HYDERABAD - 500 082. INDIA info@pmurali.com Website : www.prnurali.com We also performed procedures in accordance with the
Slide 5: Auditor's Review Report - Consolidated (continued)
Tel. : (91-40) 2332 6666, 2331 2554 P. MURALI & CO., 2339 3967, 2332 1470 CHARTERED ACCOUNTANTS FAX : (91-40) 2339 2474 6-3-655/2/3, SOMAJIGUDA, E-mail : pmura1i.co@gmail.com HYDERABAD - 500 082. !NOIA info@pmurali.com Website : www.pmurali.com The accompanying Statement includes unaudited interim f
Slide 6: Unaudited Standalone Financial Results Q1 FY23
Balaxi Pharmaceuticals Limited 2nd Floor, MAPS Towers, Plot no. -!09, Road no. 81, Jubilee Hils, Phase[!], Hyderabad-500096, Telangana CIN:L25191 TGl 9-!2PLC121598 Un-audited Standalone Financial Results for the quarter ended 30th June, 2022 (Rs. in Lakhs) Quarter Ended Year ended Particulars 30.06.
Slide 7: Auditor's Review Report - Standalone
Tel. : (91-40) 2332 6666, 2331 2554 P. MURALI & CO., 2339 3967, 2332 1470 CHARTERED ACCOUNTANTS FAX : (91-40) 2339 2474 6-3-655/2/3, SOMAJIGUDA, E-mail : pmurali.co@gmail.com HYDERABAD - 500 082. INDIA info@pmurali.com Website: www.pmurali.com Independent Auditor's Review Report on the Quarterly Una
Slide 8: Auditor's Review Report - Standalone (continued)
P. MURALI & CO., Tel. : (91-40) 2332 6666, 2331 2554 2339 3967, 2332 1470 CHARTERED ACCOUNTANTS FAX : (91-40) 2339 2474 6-3-655/2/3, SOMAJIGUDA, E-mail : pmurali.co@gmail.com HYDERABAD - 500 082. INDIA info@pmurali.com Website : www.pmurali.com Based on our review conducted as above, nothing has com
Slide 9: Branded IPR-driven Pharma Player in Frontier Markets: Q1FY23 Financial Results
Branded IPR-driven Pharma Player in Frontier Markets Q1FY23 Financial Results
Slide 10: Disclaimer
Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual
Slide 11: Contents
Contents 04 Corporate Snapshot 15 Financial Highlights 21 Strategic Roadmap 3
Slide 12: Bridging the Supply Gap in Frontier Markets
Bridging the Supply Gap in Frontier Markets Branded IPR-based pharma Presence in OTC segments including company strong branded generics portfolio Frontier markets leadership in Targeting top-2 position in each Latin America and Africa geography Vast portfolio across diverse Backed by deep distributi
Slide 13: Successful Produce, Stock, Sell Business Model
Successful Produce, Stock, Sell Business Model Established operations: Expansion initiated: Guatemala (Latin America), Dominican Republic El Salvador, Nicaragua, Ecuador, Chile Markets (Caribbean) and Angola (Africa) (Latin America) New operations: Honduras (Latin America) Central African Republic,
Slide 14: Key Success Factors
Key Success Factors Market Selection Methodology Focus on countries with high-potential economic growth framework Identify non-English speaking countries with similar characteristics Low competitive intensity and potential to establish top-2 position On-ground feedback mechanism allows deep
Slide 15: Transition from Asset Light to Asset Right
Transition from “Asset Light” to “Asset Right” Marketing and Market Research Product Identification Product Registration Manufacturing Distribution Existing Operations New Manufacturing Unit As a part of its corporate evolution, Balaxi is moving its business model from ‘Asset Light’ to ‘Asset Right’
Slide 16: Investment in Manufacturing Facilities
Investment in Manufacturing Facilities Setting up EU GMP compliant pharma manufacturing unit General Oral Solid Dosage (OSD) and Liquid Injection formulations Targeting demand for high quality products in Latin American markets Allows full backward integration of supply chain Production from Pharma
Slide 17: Global Footprint
Global Footprint Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 9
Slide 18: Key Milestones
Key Milestones Started business supplying white labelled products to customers in Africa Diversified supply chain by Products were sourced from sourcing pharma products Set-up central distribution WHO GMP certified plants from WHO GMP certified warehouse in Guatemala, based in India manufacturers in
Slide 19: Corporate Structure
Corporate Structure Balaxi Pharmaceuticals Limited Balaxi Global DMCC, Dubai (WOS) Balaxi Balaxi Balaxi Balaxi Balaxi Balaxi Healthcare Healthcare Balaxi Healthcare Healthcare Healthcare Healthcare Healthcare Dominica Guatemala Angola LDA EL Salvador Honduras Central African Angola LDA SRL (WOS) S.A
Slide 20: Experienced Board of Directors
Experienced Board of Directors Ashish Maheshwari Minoshi Maheshwari Kunal Bhakta Chairman & Managing Director Non-Executive Director Independent Director Founder of the company, first Co-founder, 20 years of rich Chartered Accountant with 15 years’ generation entrepreneur, qualified experience with
Slide 21: Strong Leadership Team
Strong Leadership Team Ashish Maheshwari Amol Mantri Chairman & Managing Director CFO Founder of the company, first generation Qualified Chartered Accountant and Certified Public entrepreneur, qualified Chartered Accountant Accountant from USA Commenced business by supplying white labelled Associate
Slide 22: Regional Teams
Regional Teams Jignesh Dinesh Kumar Shah Laksh Shewakramani Ram Chawla Financial Controller – Angola Compliance Head – Angola Country Head – Angola Pankaj Singh Manish Jumnani Head of Operations– Guatemala Sales Head – Guatemala Karan Kapoor Bharat Jawarani Head of Operations – Sales Head – Dominica
Slide 23: Financial Highlights
FINANCIAL HIGHLIGHTS Balaxi
Slide 24: Management's Comments
Management’s Comments “Our revenue growth of 42% during Q1 is driven by strong volume contribution from Latin American markets. We have also derived translation benefits from a strong currency in Angola. Gross margin expanded significantly, once again based on the strength of the growing Latin Ameri
Slide 25: Quarterly Financial Performance
Quarterly Financial Performance Particulars (INR Crore) Q1FY23 Q1FY22 YoY Revenue 82.78 58.34 +41.9% Gross Profit 34.52 16.8 +105.5% Gross Margin % 41.7% 28.8% 1,290 bps EBITDA 17.03 12.55 +35.6% EBITDA Margin % 20.6% 21.5% (95) Bps Profit After Tax 14.15 10.71 +32.1% PAT Margin % 17.1% 18.4% (127)
Slide 26: Pharma Product Mix – Q1 FY23
Pharma Product Mix – Q1 FY23 Geographies Products 1% Angola Shareholders’ 22% Debt Fixed Assets Working Capital Funds Guatemala 35% Branded Dominican Generics 15% 62% Republic 65% Honduras Dosage Forms Therapeutic Areas 12% Tablets Antibiotics 36% 37% 14% Injectables Analgesic 47% Liquids Anti-malar
Slide 27: Historical Financial Performance
Historical Financial Performance Particulars (INR Crore) FY22 FY21 YoY Revenue 279.39 231.33 +20.8% Gross Profit 83.79 59.19 +41.6% Gross Margin % 30.0% 25.6% +440 bps EBITDA 55.18 44.64 +23.6% EBITDA Margin % 19.7% 19.3% +45 bps Profit After Tax 47.66 38.14 +25.0% PAT Margin % 17.1% 16.5% +60 bps E
Slide 28: Pharma Product Mix – FY22
Pharma Product Mix – FY22 Geographies Products Shareholders’ Angola 28% Debt Fixed Assets Working Capital Funds 30% Guatemala Branded Generics 59% 13% Dominican Republic 70% Dosage Forms Therapeutic Areas 12% Tablets Antibiotics 31% Injectables 41% 13% 46% Analgesic Liquids Anti-malaria 12% Capsules
Slide 29: Core Strategy: Enter, Expand & Excel
Core Strategy: Enter, Expand & Excel Balaxi in 2020: Business Consolidation Presence across Angola, Guatemala and Dominican Republic Effective and efficient supply chain model consisting of 38 warehouses and a fleet of owned vehicles Balaxi in 2021-22: Expansion into New Geographies Aim to cap
Slide 30: Thank You
Plot No. 409, H.No. 8-2-293, 2nd Floor Maps Towers, Jubilee Hills, Road No:81,Hyderabad. Telangana CIN: L25191TG1942PLC121598 Company Investor Relations contact Mr. Sunny Purohit +91-40-2355-5300 sunny@balaxi.com www.balaxipharma.in BALAXI BALAXI:IN Thank You
Slide 31: Balaxi Pharmaceuticals reports continued solid growth in Q1 FY23
Annexure 3 Press Release For Immediate Release Balaxi Pharmaceuticals reports continued solid growth in Q1 FY23 Revenue grows 42% in Q1FY23 Pharma Revenue in Latin America up 39% Profit After Tax up 32% YoY Hyderabad, August 2, 2022: Balaxi Pharmaceuticals Limited (Balaxi), a branded IPR-based pharm
Slide 32: Press Release (continued): Operating costs and manufacturing facility
The company’s operating cost structure – both people and organizational costs – has increased substantially with the entry into several new markets. This includes establishment and product registration expenses in countries that are not contributing to sales at present. Going forward, as business sc
Balaxi Pharmaceuticals — Q1 FY2023 Earnings Presentation on 6ix